Scarica l'app Stockscreener
114.48
3.57%
-4.24
Pre-mercato:
114.41
-0.07
-0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week - MSN
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.59 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Illumine Investment Management LLC Invests $1.30 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
GW&K Investment Management LLC Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Los Angeles Capital Management LLC Has $70 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NasdaqGS:NBIX) Highlights INGREZZA's Positive Phase 4 Study Results - Simply Wall St
Neurocrine Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Peloton Wealth Strategists - MarketBeat
Phase IV Ingrezza data move focus from sales outlook - The Pharma Letter
NBIXNeurocrine Biosciences Inc Latest Stock News & Market Updates - StockTitan
Blackhawk Capital Partners LLC. Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
C WorldWide Group Holding A S Boosts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Impax Asset Management Group plc Acquires 176,599 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine's Phase 4 Study Shows INGREZZA Improves Quality Of Life For Tardive Dyskinesia Patients - Nasdaq
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures - PR Newswire
Endometriosis Market Predicted to See Upsurge Through 2034, - openPR
Neurocrine Biosciences (NASDAQ:NBIX) Receives Buy Rating from HC Wainwright - MarketBeat
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Hussman Strategic Advisors Inc. - MarketBeat
Endometriosis Pipeline Drugs Analysis Report: FDA Approvals, - openPR
Neurocrine Biosciences authorizes $500M share repurchase program - MSN
Q3 EPS Forecast for Neurocrine Biosciences Cut by Analyst - MarketBeat
Vontobel Holding Ltd. Sells 6,148 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now? - Insider Monkey
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality - Simply Wall St
Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
DSM Capital Partners LLC Has $127.30 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. authorizes a Buyback Plan. -February 20, 2025 - Marketscreener.com
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program - Marketscreener.com
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts - Benzinga
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
Neurocrine Biosciences sets $500M share buyback plan By Investing.com - Investing.com South Africa
Neurocrine Biosciences sets $500M share buyback plan - Investing.com India
Neurocrine Biosciences Approves $500 Million Share Repurchase Program -February 21, 2025 at 08:19 am EST - Marketscreener.com
Neurocrine Board Authorizes Share Repurchase ProgramQuick Facts - Nasdaq
Neurocrine Biosciences (NBIX) Announces $500M Share Buyback - StreetInsider.com
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program - PR Newswire
Leerink Partnrs Issues Optimistic Outlook for NBIX Earnings - MarketBeat
Rice Hall James & Associates LLC Sells 6,785 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by StockNews.com - MarketBeat
AlphaCentric Advisors LLC Sells 18,816 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Ieq Capital LLC Increases Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Van ECK Associates Corp Buys 9,824 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
New York State Teachers Retirement System Cuts Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Matt Abernethy Sells 2,558 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January - Insider Monkey
Neurocrine Biosciences chief legal officer sells $107,727 in stock - MSN
Neurocrine Biosciences' chief corporate affairs officer sells shares worth $208,387 - MSN
Neurocrine Biosciences CFO Matt Abernethy sells $115,908 in stock - MSN
Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts By Investing.com - Investing.com Nigeria
Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts - Investing.com
Stanley Laman Group Ltd. Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Sees Large Decrease in Short Interest - MarketBeat
Neurocrine Biosciences CHRO sells shares worth $181,129 - MSN
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 5,844 Shares of Stock - MarketBeat
1.08%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):